ストックスクリーナーアプリを入手
0.7675
2.23%
-0.0175
アフターアワーズ：
.76
-0.0075
-0.98%
Caribou Biosciences Inc (CRBU) 最新ニュース
Thrivent Financial for Lutherans Acquires 79,636 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Caribou Biosciences stock hits 52-week low at $0.71 - Investing.com India
Caribou Biosciences stock hits 52-week low at $0.71 By Investing.com - Investing.com South Africa
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation - Markets Insider
Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Consensus Target Price from Analysts - Defense World
Caribou Biosciences stock hits 52-week low at $0.95 By Investing.com - Investing.com Canada
Caribou Biosciences stock hits 52-week low at $0.95 - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Investors to Learn More About the Investigation - Markets Insider
Caribou Biosciences’ (CRBU) “Buy” Rating Reiterated at HC Wainwright - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out - Markets Insider
Caribou Biosciences’ SWOT analysis: CRISPR pioneer’s stock faces critical juncture - Investing.com Canada
Truist Removes Price Target on Caribou Biosciences, Keeps Buy Rating; Price Target Was $19 - Marketscreener.com
US Bancorp DE Buys 26,467 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect - Markets Insider
Caribou Biosciences CEO Rachel E. Haurwitz buys $20,400 in stock By Investing.com - Investing.com Australia
Caribou Biosciences CEO Rachel E. Haurwitz buys $20,400 in stock - Investing.com India
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates - MSN
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Analysts Remain Bullish on Caribou Biosciences (CRBU) Despite Ongoing Slump in its Shares - Markets Insider
Caribou Biosciences stock hits 52-week low at $1 By Investing.com - Investing.com Australia
Caribou Biosciences stock hits 52-week low at $1 - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
CRBU FY2029 EPS Reduced by Brookline Capital Management - Defense World
Caribou Biosciences Brass Face Investor's Clinical Trials Suit - Law360
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - GuruFocus.com
Caribou Biosciences Advances CRISPR Therapies Amid Financial Challenges - TipRanks
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation - Markets Insider
RBC Cuts Price Target on Caribou Biosciences to $11 From $14, Keeps Outperform, Speculative Risk - Marketscreener.com
Caribou Biosciences reports Q4 EPS (39c), consensus (42c) - TipRanks
Caribou Biosciences shares rise on narrower-than-expected Q4 loss By Investing.com - Investing.com Australia
Caribou Biosciences shares rise on narrower-than-expected Q4 loss - Investing.com India
Caribou Biosciences, Inc. SEC 10-K Report - TradingView
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Caribou Biosciences, Inc. Anticipates Clinical Data from CB-010 and CB-011 in H1 2025 Amidst Advancements in Hematologic Malignancies and Autoimmune Disease Therapies - Nasdaq
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... - The Bakersfield Californian
Caribou Biosciences, Inc. Sued for Securities Law ViolationsI - GuruFocus.com
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Caribou Biosciences Leaders Overhyped Cancer Therapy, Suit Says - Bloomberg Law News
Caribou Biosciences (CRBU) Expected to Announce Quarterly Earnings on Monday - Defense World
Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Consensus PT from Analysts - Defense World
3.01%
大文字化:
|
ボリューム (24 時間):